Cagrilintide vs Oxyntomodulin

Long-acting amylin analogue; acts on amylin/calcitonin receptors to prolong satiety; synergistic with semaglutide in CagriSema combination

Cagrilintide is a long-acting synthetic amylin analogue under clinical development for obesity, designed to mimic the satiety-promoting and gastric-emptying-reducing actions of the endogenous beta-cell hormone amylin. By activating amylin receptors in the hindbrain, cagrilintide reduces caloric intake and body weight, and the drug is also being co-developed with the GLP-1 receptor agonist semaglutide (CagriSema) to target multiple appetite-regulating pathways simultaneously. Phase 2 randomized controlled trials published in The Lancet have demonstrated meaningful weight reduction in people with overweight and obesity, establishing proof of concept for both monotherapy and combination approaches. Cagrilintide is an investigational compound that has not yet received FDA approval; it remains in late-stage clinical development as of 2025.

Dual GLP-1/glucagon receptor agonist. GLP-1 component suppresses appetite; glucagon component increases energy expenditure and fatty acid oxidation. Net effect is reduced caloric intake and elevated metabolic rate.

Oxyntomodulin is an endogenous 37-amino-acid proglucagon-derived peptide co-secreted with GLP-1 and PYY by intestinal L-cells in response to nutrient ingestion, distinguished from GLP-1 by a C-terminal octapeptide extension that enables dual agonism at both the GLP-1 receptor and the glucagon receptor, producing combined effects on appetite suppression, energy expenditure, and glucose homeostasis. GLP-1 receptor activation by oxyntomodulin reduces food intake through central satiety signaling, while concurrent glucagon receptor activation stimulates hepatic glucose production, thermogenesis in brown adipose tissue, and elevated energy expenditure — a combination that theoretically produces greater weight loss than GLP-1 receptor activation alone while the glucogenic and GLP-1 effects approximately offset each other's glycemic impact. A double-blind randomized controlled trial of subcutaneous oxyntomodulin in overweight and obese human subjects demonstrated significant body weight reduction versus placebo over a 4-week treatment period, establishing proof-of-concept for dual GLP-1/glucagon receptor co-agonism as a human anti-obesity mechanism and validating the pharmacological rationale for long-acting dual agonist drug development programs. Native oxyntomodulin has no FDA approval; its short plasma half-life from DPP-IV degradation precludes clinical development in its native form, and commercial research interest has shifted to stabilized long-acting dual agonist analogs such as cotadutide and retatrutide, which use this dual mechanism in engineered molecules with drug-like pharmacokinetics.